Related by context. All words. (Click for frequent words.) 65 IMPROVE HF 64 TAXUS IV 64 HORIZONS AMI trial 64 TAXUS VI 64 CYPHER ® Stent 63 OLYMPIA registry 63 clinical pharmacology studies 63 PRECiSE 63 drug eluting stent DES 63 RE LY ® 62 viral kinetic 62 EchoCRT 62 STRIDE PD 62 CYPHER Stent 62 SPIRIT IV 62 ONTARGET 62 ASPIRE HIGHER 62 placebo controlled clinical 62 RE LY 62 AIM HIGH 62 SYNTAX trial 62 LUMINATE 62 CIMZIA ™ 61 RESOLUTE clinical 61 ENDEAVOR II 61 BARI 2D 61 placebo controlled Phase III 61 Endeavor DES 61 sunitinib malate 61 angiographic outcomes 61 LUX Lung 61 TAXUS V 61 TEMSO 61 teriflunomide 61 Meta analyzes 61 GAMMAGARD 61 PLCO 61 SCD HeFT 61 TAXUS Liberte 61 multicenter trials 61 Phase #/#a 61 CYPHER R Sirolimus eluting 60 MIVI TRUST 60 ABSORB trial 60 phase IIa clinical 60 BCIRG 60 COPAXONE R 60 NCCTG 60 PFO migraine 60 phase IIb clinical 60 Phase Ib II 60 riociguat 60 SPIRIT FIRST 60 paclitaxel eluting stent 60 everolimus eluting stent 60 TAXUS Liberte Stent 60 Resolute DES 60 SWOG 60 ENDEAVOR IV 60 confirmatory clinical 60 CAMMS# 60 TAXUS Stent 60 VIDAZA azacitidine 60 ROCKET AF 60 AVADO 60 phase IIIb 60 relapsed MM 59 MERLIN TIMI 59 ACRIN 59 Vascugel ® 59 RenalGuard System TM 59 retrospective cohort 59 ADVANCE PD 59 MADIT II 59 sipuleucel T 59 phase IIb trial 59 TRITON TIMI 59 PSMA ADC 59 drug eluting coronary stent 59 EVEREST II 59 ischemic cardiomyopathy 59 RTOG 59 pharmacokinetic PK 59 HF ACTION 59 TAXUS TM 59 Zemplar Capsules 59 nonrandomized 59 oncologic outcomes 59 ER CHOP 59 TG MV 59 NSABP B 58 ACS NSQIP 58 NSABP 58 XIENCE V Everolimus Eluting 58 CYPHER R Stent 58 mm Stent 58 dosing cohort 58 PreCISe 58 pharmacodynamic PD 58 ORMD 58 randomized controlled clinical 58 PROactive study 58 Carotid Revascularization Endarterectomy vs. 58 Endeavor stent 58 PERSEUS 58 standard chemotherapy regimen 58 randomized controlled clinical trials 58 SUCCEED trial 58 oral FTY# 58 Randomized Evaluation 58 preclinical efficacy 58 QTinno 58 evaluating mipomersen 58 dose escalation Phase 58 Endeavor drug eluting 58 AIR2 Trial 58 Framingham Offspring Study 58 PRESEPT 58 evaluating REVLIMID 58 MEND CABG 58 carotid artery stenting 58 ARCOXIA 58 DAPT Study 58 BIIR 58 NeuroFlo 58 placebo controlled Phase 58 cardio renal 58 azilsartan medoxomil 58 CARE HF 58 Group RTOG 58 coronary stenting 58 antithrombotic therapy 58 trastuzumab emtansine T DM1 58 NEVO RES 58 randomized Phase III 58 ToGA 58 CALGB 58 Phase Ib study 58 elotuzumab 58 trials RCTs 58 double blinded randomized 58 ongoing Phase IIIb 58 Halozyme Ultrafast Insulin 58 Azedra 58 Phase IIB 58 prospective multicentre 58 MGd 58 CLL8 58 TAXUS 57 viral kinetics 57 budesonide MMX Phase III 57 definite stent thrombosis 57 everolimus eluting stents 57 Dialysis Outcomes 57 Alocrest 57 registrational 57 CTSAs 57 NATRECOR ® 57 multicenter Phase 57 stent DES 57 Corus CAD 57 phase IIa 57 carotid artery stenting CAS 57 torcetrapib atorvastatin 57 prospective observational studies 57 Clinical Antipsychotic Trials 57 NO# [002] 57 ICD therapy 57 pomalidomide 57 prospective nonrandomized 57 eprotirome 57 YONDELIS 57 NICE SUGAR 57 placebo controlled studies 57 cediranib 57 LibiGel Phase III 57 Exelixis XL# 57 PORxin TM platforms 57 ACCORD Lipid 57 NCCTG N# 57 ZoMaxx 57 PROLARIS 57 mg BID dose 57 prospective multicenter randomized 57 NLX P# 57 cinacalcet 57 HuLuc# 57 GetGoal Phase III 57 tanespimycin 57 atherothrombotic disease 57 microplasmin Phase III 57 Stenting Trial CREST 57 APPRAISE 57 axitinib 57 GENASIS trial 57 ExTRACT TIMI 57 MADIT CRT trial 57 intensive lipid lowering 57 TAXUS ATLAS 57 carotid stent 57 XIENCE V stent 57 ASCEND HF 57 PressureWire 57 SPIRIT III 57 ARB telmisartan 57 observational cohort 57 MTWA testing 57 REMINYL ® 57 CIMZIA TM 57 afatinib 57 Endeavor Resolute 56 binary restenosis 56 PROMUS Element Stent 56 multicenter clinical trials 56 alvespimycin 56 enzastaurin 56 multicentre randomized 56 APTIVUS 56 Coronary stent 56 TOLAMBA 56 HCV SPRINT 56 plasmid DNA vaccine 56 GFT# 56 tesmilifene 56 Genz # 56 substudy 56 prospective randomized controlled 56 Phase 2a trial 56 randomized clinical trials 56 Prostate AdenoCarcinoma Treatment 56 randomized multicenter trial 56 prospective multicenter 56 Cotavance 56 Cypher Stent 56 lintuzumab 56 HSCT 56 p# biomarker 56 bronchial thermoplasty 56 ICD implants 56 DAPT 56 REACH Registry 56 XIENCE PRIME 56 multicentre 56 Dataflow Manager 56 prospectively defined 56 MitraClip device 56 lumiliximab 56 Thorough QT 56 NSQIP 56 CardioFit 56 lorcaserin Phase 56 ACUITY trial 56 PERSEUS clinical program 56 antithrombotic therapies 56 CTRC AACR San Antonio 56 symptomatic VTE 56 Phase Ib clinical 56 HORIZONS AMI 56 blinded randomized placebo controlled 56 prospective observational cohort 56 HuMax EGFr 56 cerebral oximetry 56 exploratory endpoints 56 Bezielle 56 CSF Assurance 56 TAXUS stent 56 NEVO 56 EURIDIS 56 CATIE AD 56 BRIM2 56 PROTECT II 56 Amrubicin 56 ALN RSV program 56 Intervention Effectiveness 56 Phase 1a 56 Vascular Wrap 56 vorinostat 56 Prostate Cancer Prevention 56 efficacy endpoint 56 bazedoxifene conjugated estrogens 56 DF HCC 56 multicenter clinical 56 CR# vcMMAE 56 UVIDEM 56 phase Ib 56 AREDS 56 HGS# 56 KRAS mutations occur 56 Phase #b/#a 56 ABSORB clinical 56 HER2 positive metastatic breast 56 Intervention Effectiveness CATIE 56 Xelox 56 CLARITY study 56 Phase 1a clinical 56 SNT MC# 56 Macroplastique 56 randomized controlled trials RCTs 56 AIR CF2 56 tolerability pharmacokinetics 56 Ovarian PLCO Cancer 56 LHRH antagonists 56 Phase 1b 56 pegylated liposomal doxorubicin 56 MADIT CRT 56 ToxCast TM 56 elacytarabine 56 drug eluting coronary stents 56 MoxDuo TM IR 56 serum clusterin levels 56 retrospective cohort study 56 Combo Stent 56 coronary intervention 56 COR Analyzer 56 carotid stenting 56 MIST II 56 SYNTAX 56 Vasogen Celacade 56 randomizing patients 55 Screening Trial 55 ADHF 55 Syllego system 55 ICAEL 55 RELOVAIR ™ 55 HPTN 55 COU AA 55 pharmacokinetic characteristics 55 perampanel 55 TRA 2P 55 INTEGRILIN 55 enoximone 55 CANCIDAS 55 endovascular therapy 55 Renal Cell Carcinoma RCC 55 Stenting Trial 55 carotid artery stent 55 Phase 1b trial 55 bioabsorbable stent 55 immunosuppressive regimens 55 OPT CHF 55 CINQUIL 55 blinded randomized 55 PRIMO CABG2 55 paclitaxel eluting 55 Sorafenib HCC Assessment 55 Phase III ThermoDox 55 lipid lowering therapy 55 zotarolimus 55 BioZ ICG 55 VADT 55 prelicensure 55 Acute Decompensated Heart Failure 55 PRoFESS 55 AeroLEF TM 55 MYTHOS trial 55 muraglitazar 55 placebo controlled multicenter 55 TAXUS Liberte stent 55 LEUKINE 55 RRMS patients 55 Taxus Stent 55 dose melphalan 55 retinal vein occlusion 55 prospective longitudinal 55 randomized clinical 55 EOquin TM 55 PARTNER Trial 55 INTERCEPT platelets 55 RG# ITMN 55 dyslipidaemia 55 pharmacokinetic pharmacodynamic 55 meta analyzes 55 GWTG CAD 55 BRIM3 55 PreCISe study 55 INxin TM 55 skin sterol 55 pain palliation 55 placebo controlled trials 55 ARCALYST ® rilonacept 55 AVOREN 55 randomized Phase 2b 55 CHAMPION PCI 55 zotarolimus eluting stent 55 Atherosclerosis MESA 55 secondary efficacy endpoints 55 TMC# C# 55 tipranavir 55 ascending dose 55 EDEMA3 55 KRAS status 55 ATACAND 55 alicaforsen enema 55 desvenlafaxine succinate 55 Multicenter Automatic Defibrillator Implantation 55 chemoprevention trials 55 Val HeFT 55 postoperative chemotherapy 55 multicenter multinational 55 sirolimus eluting stents 55 Dr. Kandzari 55 prospective observational 55 KRAS variant 55 ELCAP 55 transcatheter aortic valve implantation 55 posaconazole 55 REVIVE TA 55 relapsing multiple sclerosis 55 multicenter phase 55 multicenter placebo controlled 55 Phase IIa trials 55 Phase 2b 55 PROSTVAC TM 55 RE LY trial 55 Ceplene/IL-2 55 Lp PLA 2 55 retrospective observational study 55 methodologically rigorous 55 PROactive Study 55 bendamustine 55 Outpatient Setting 55 GISSI HF 55 phase IIb study 55 Phase IIIb 55 analgesic efficacy 55 metastatic CRC 55 sirolimus eluting stent 55 Phase 2b study 55 multicenter study 55 NATRECOR R 55 BEXXAR therapeutic regimen 55 lomitapide 55 NEVO ™ 55 COPERNICUS 55 recurrent glioma 55 SABCS 55 Alzheimer Disease Cooperative 55 CUSTOM III 55 ILLUMINATE 55 prospectively randomized 55 tolvaptan 54 ELACYT 54 NABTT 54 azacitidine 54 adenoma recurrence 54 pramlintide metreleptin combination 54 DMIST 54 VerifyNow P#Y# Test 54 cPAX 54 Phase 2b kidney transplant 54 ENDEAVOR III 54 MarginProbe 54 iniparib BSI 54 postmenopausal osteoporotic women 54 neratinib 54 carotid endarterectomy CEA 54 atrasentan 54 CCX# 54 Phase Ib 54 Pharmacokinetic parameters 54 Ovarian Cancer Screening 54 Betaferon ® 54 PD2i ® 54 eculizumab therapy 54 bladder augmentation 54 thoracoscopic lobectomy 54 Phase III ADT 54 CAPRISA 54 Phase III placebo controlled 54 CYPHER ® Sirolimus eluting 54 Non inferiority 54 randomized blinded 54 Thrombolysis 54 Mylotarg 54 longitudinal cohort study 54 secondary efficacy endpoint 54 rALLy clinical trial 54 MitraClip 54 PROMUS Element Everolimus Eluting 54 TAXUS Express Stent 54 null responder HCV 54 NHANES III 54 Phase III psoriasis 54 pharmacodynamic effects 54 HepaMate 54 XIENCE V demonstrated 54 AngioJet System 54 deferiprone 54 ADMIRE HF 54 Octreolin 54 Phase IIIb clinical 54 CYPHER ® 54 randomized multicenter Phase III 54 multicenter prospective 54 Angiox R 54 rEEG 54 APEX PD 54 MitraClip R 54 concurrent chemoradiation 54 pertuzumab 54 dacarbazine chemotherapy 54 Trofex 54 ACTIVE W 54 percutaneous interventions 54 patients undergoing CABG 54 FAME Study 54 BioNumerik 54 NSABP C 54 radiographic outcomes 54 TAXUS Stents 54 low dose cytarabine 54 REALITY Trial 54 randomized controlled Phase 54 TMC# r 54 ICON7 54 quadrivalent HPV vaccine 54 randomized trials 54 GORE VIABAHN Endoprosthesis 54 pivotal bioequivalence 54 Translational Science Award 54 Virtual Histology 54 subgroup analyzes 54 interferon gamma 1b 54 imetelstat 54 AIR CF3 54 LCP AtorFen 54 vitro ADME 54 HeFT 54 phase IIb 54 noninferiority 54 GPNMB expression 54 mg/m2 cohort 54 QTinno TM 54 multicenter randomized Phase 54 ThinPrep Pap Test 54 iniparib 54 active comparator 54 multicenter 54 prospective randomized multicenter 54 GRAVITAS trial 54 hemodialysis patients 54 Phase 2a clinical 54 darapladib 54 Secondary efficacy endpoints 54 PROMUS 54 oral ridaforolimus 54 aldosterone antagonists 54 micafungin 54 retrospective observational 54 DXL TM 54 AIR CF1 54 metastatic RCC 54 APEX AMI trial 54 null responder 54 pegylated interferon alfa 2b 54 MSI #F 54 Phase #b/#a clinical 54 CYPHER R stent 54 multicenter randomized clinical 54 Digital Mammographic Imaging 54 AVERROES 54 PRE SURGE 54 prognostic variables 54 pharmacokinetic PK study 54 UKPDS 54 metaanalysis 54 Angiographic 54 MGuard ™ 54 ISEL 54 brivaracetam 54 UroVysion 54 acyclovir Lauriad R 54 EUS FNA 54 Phase 2b monotherapy 54 controlled multicenter 54 pharmacogenetic testing 54 sorafenib Nexavar 54 oral diclofenac 54 EXPLORE Xa 54 PICSO ® 54 MoxDuo IR 54 randomized multicenter 54 metaglidasen 54 GRNCM1 54 Zenvia Phase III 54 PCPT 54 multicenter randomized controlled 54 elagolix 54 FFR guided treatment 54 idraparinux 54 Neuradiab 54 nonsquamous 54 CLIRS 54 R0 resection 54 Long Lesion 54 Powerlink System 54 PROPEL trial 53 Xience Prime 53 TQT 53 multicenter Phase III 53 LEXIVA r 53 peg interferon 53 Coronary Stent 53 velafermin 53 PACCE trial 53 dose cohorts 53 subanalysis 53 CRESTOR #mg 53 relapsing remitting MS RRMS 53 gadobutrol 53 ONTARGET R 53 dose escalation 53 heavily pretreated patients 53 ACCORD Eye 53 pazopanib 53 clinically localized prostate 53 Doxil ® 53 TACI Ig 53 undetectable HBV DNA 53 BOLDER II 53 assessing T DM1 53 ChronVac C R 53 MADIT 53 MEND CABG II 53 CALGB # [002] 53 AZOR 53 EORTC 53 Vaxfectin R 53 Prostate Lung Colorectal 53 Wisconsin Sleep Cohort 53 TORISEL 53 ICD implantations 53 RECORD1 53 Edge STudy 53 sustained virological response 53 fondaparinux 53 GPRD 53 evaluable subjects 53 ALLHAT 53 placebo controlled 53 sustained virologic response 53 motesanib diphosphate 53 TAXUS Element Stent System 53 XIENCE V PROMUS Stent 53 Velcade bortezomib 53 vidofludimus 53 olaparib 53 XIENCE 53 eplerenone 53 Dacogen injection 53 Radiation Therapy Oncology 53 tocilizumab 53 HCV RESPOND 2 53 PRADAXA 53 antidiabetic therapy 53 CHARM Added 53 RSD# oral 53 NADiA 53 lymphadenectomy 53 Diabetic Macular Edema 53 Oncotype DX colon cancer 53 ADAGIO study 53 haplotype map 53 adjuvant endocrine therapy 53 CERVARIX 53 Edwards SAPIEN valve 53 EmbraceAC 53 peginterferon 53 preclinically 53 Zilver PTX stent 53 Thorough QT TQT 53 EDEMA3 trial 53 NAVISTAR R 53 phase III ACCLAIM 53 Innovent Oncology 53 abiraterone acetate 53 SYMMETRY trial 53 Resolute drug eluting 53 immatics 53 Trandolapril 53 neoadjuvant 53 Phase 2b clinical 53 Cloretazine 53 AEG# 53 rt PA 53 neoadjuvant treatment 53 PhG alpha 1 53 TAXUS Liberte Long 53 Androxal TM 53 Protein Structure Initiative 53 CYPHER R 53 samalizumab 53 fully bioabsorbable 53 intravascular ultrasonography 53 R#/MEM # 53 Ranolazine 53 EECP therapy 53 acute ischemic stroke 53 OZURDEX ® 53 XIENCE TM 53 mSEPT9 biomarker 53 atherosclerosis regression 53 EQUIP OB 53 irbesartan 53 PRTX 53 sunitinib 53 MAGE A3 ASCI 53 symptomatic BPH 53 flurpiridaz F 53 OmniWave 53 ixabepilone 53 phase 2a 53 Acute Ischemic Stroke 53 transfemoral 53 HeFH 53 Drug eluting stent 53 pharmacodynamic 53 invasive candidiasis 53 virologic response 53 #F FDG PET 53 bevacizumab Avastin 53 Solesta 53 Randomized clinical trials 53 percutaneous vertebroplasty 53 composite endpoint 53 PECARN 53 thrombolytic agents 53 VITAL Trial 53 ARDIS 53 IMPACT DCM 53 sNDA submission 53 echocardiographic parameters 53 sirolimus eluting 53 neoadjuvant chemotherapy 53 HydroCoil 53 colorectal liver metastases 53 recurrent glioblastoma multiforme 53 prospective multicenter study 53 WallFlex Biliary RX 53 gauge vitrectomy 53 EGS# 53 retinal thickness 53 oral anticoagulation 53 antitumor effect 53 NSTE ACS 53 Stent Thrombosis 52 Group B CALGB 52 antithrombotic 52 CIPN 52 ACC AHA 52 randomized controlled 52 Intervention Trial GAIT 52 autologous SCT 52 Screening Trial DMIST 52 dose escalation phase 52 Asthma Intervention 52 morphometric vertebral fractures 52 RPGEH 52 paclitaxel eluting stents 52 trastuzumab DM1 T DM1 52 Zenvia ™ 52 iPrEx 52 liver transplantations 52 carotid IMT 52 cystinosis patients 52 cat dander allergy 52 lipid lowering agents 52 cathepsin K inhibitor 52 Fractional Flow Reserve 52 Novartis Zometa 52 Affymetrix microarray technology 52 ACOSOG Z# 52 antiangiogenic agents 52 placebo controlled clinical trials 52 Study AREDS 52 xTAG RVP 52 STEP BD 52 aspirin clopidogrel 52 PK PD modeling 52 AZILECT R 52 GORE TAG Device 52 oral deforolimus 52 atherothrombotic events 52 NIH Roadmap 52 thrombus aspiration 52 atherothrombosis 52 EMPHASIS HF 52 ARIXTRA 52 anti arrhythmic drug 52 stable angina 52 Phase III 52 ThermoDox ® clinical 52 CaPSURE 52 PRIMO CABG 52 CATIE 52 renal tumors 52 End Results SEER 52 HIVNET 52 chemotherapeutic regimen 52 prespecified 52 genotypic resistance 52 solithromycin 52 miRview ™ mets 52 Myocardial Infarction Study 52 CYT# potent vascular disrupting 52 cannabinor 52 Folfox 52 ABSORB 52 Tryton Side Branch 52 TACE 52 functional mitral regurgitation 52 ACTEMRA 52 depsipeptide 52 candesartan cilexetil 52 levosimendan 52 PRESEPT study 52 CIMZIA TM certolizumab pegol 52 methotrexate therapy 52 ABCSG 52 Phase III randomized controlled 52 GWTG 52 odanacatib 52 masked placebo controlled 52 refractory angina 52 TAXUS ARRIVE 52 goserelin 52 basal bolus regimen 52 antithrombotic agents 52 Zevalin consolidation 52 AneuRx 52 canakinumab 52 NEO3 52 Inhaled nitric oxide 52 ENGAGE AF TIMI 52 ASTEROID 52 paclitaxel eluting coronary stent 52 EBUS FNA 52 neurocognitive outcomes 52 vildagliptin 52 Cervista HPV HR 52 Valsartan 52 alvimopan 52 liver transplant recipients 52 Phase III VISTA 52 NeuroStar TMS Therapy 52 coronary revascularization 52 potent antiretroviral therapy 52 Dose escalation 52 metastatic HRPC 52 lipid lowering drugs 52 nab paclitaxel 52 FDG PET imaging 52 Swedish Mammography Cohort 52 tiotropium 52 carotid stents 52 Aflibercept 52 MGCD# clinical trials 52 antiplatelet therapies 52 clinical trial 52 ximelagatran 52 eluting coronary stent 52 Lenocta 52 subcutaneous PRO 52 PCWP 52 inhibitor RG# 52 ALSYMPCA 52 Baseline characteristics 52 Candesartan 52 antiplatelet agents 52 Human Hookworm Vaccine Initiative 52 CRp 52 rALLy trial 52 Virulizin ® 52 NHANES 52 Phase Ia 52 ancrod 52 Phase IIIb study 52 chronic periodontitis 52 multicentre prospective 52 Women Ischemia Syndrome 52 preoperative chemotherapy 52 mixed hyperlipidemia 52 certolizumab 52 NCT# ClinicalTrials.gov 52 elective PCI 52 mechanical thrombectomy 52 multicenter Phase II 52 Trial PCPT 52 graft patency 52 OPCAB 52 Rilonacept 52 Pivotal Trial 52 Peptidomics 52 melphalan prednisone 52 dobutamine stress 52 antiarrhythmic drug 52 Reynolds Risk Score 52 multicenter randomized placebo controlled 52 unfractionated heparin UFH 52 β blockers 52 preclinical pharmacokinetic 52 dirucotide MBP# 52 Onrigin TM 52 cortical stimulation 52 placebo controlled randomized 52 complete cytogenetic response 52 antithrombotics 52 candesartan 52 TAXUS Liberté 52 MDV# 52 ACTEMRA TM 52 eTag assays 52 urocortin 2 52 Element Stent 52 Estybon ™ 52 atherogenic dyslipidemia 52 MOTIVATE 52 thorough QT 52 aerosolized KL4 surfactant 52 chemoradiotherapy 52 ICD Registry 52 Atherothrombosis 52 Aggressive Drug Evaluation 52 myoblast therapy 52 European Sepsis Trial 52 Rheos System 52 RECIST Response Evaluation Criteria 52 PD2i R 52 mycophenolate mofetil 52 ThromCat 52 treatment naïve genotype 52 Primary endpoints 52 Targretin capsules 52 Fabry Disease 52 fidaxomicin Phase 52 PNH patients 52 Oncotype DX breast cancer 52 PASI scores 52 Targretin 52 biostatistical analysis 52 excavator trenching 52 Eluting Coronary Stent System 52 carotid revascularization 52 virological response 52 nondiabetic patients 52 blind randomized controlled 52 Secondary endpoints 52 Randomized controlled 52 Zilver PTX 52 surrogate endpoint 52 Multi MERCI 52 death reinfarction 52 DU #b 52 oral rivaroxaban 52 Vectibix monotherapy 52 QuadraSphere 52 DIABECELL ® 52 IN.PACT Falcon 52 #:# randomization 52 VersaFilm 52 ibandronate 52 recurrent GBM 52 ENESTnd 52 Intravenous CP 52 Liraglutide Effect 52 cobiprostone 52 Multicenter AIDS 52 OvaRex MAb 52 Phase 2b dose 51 histologically confirmed 51 Anti Bacterial Envelope 51 observational cohort study 51 blinded randomized controlled 51 Bayer HealthCare Onyx Pharmaceuticals 51 factorial design 51 prospectively stratified 51 meta analysis 51 AlloMap 51 insulin detemir 51 SCIg 51 chronic myocardial ischemia 51 visceral metastases 51 GP IIb IIIa inhibitor 51 statin monotherapy 51 Phase #/#a trial 51 CTEPH 51 XL# SAR# 51 perioperative mortality 51 study1 51 Xience V stent 51 TAXUS Element Stent 51 Elocalcitol 51 PNH Registry 51 CaPre TM 51 PROMUS Element 51 glatiramer acetate 51 alteplase 51 CLBP 51 risk stratification